Retifanlimab Emerges as Potential New SOC in Advanced SCAC
Following encouraging efficacy seen in patients with locally advanced Merkel cell carcinoma (MCC), investigators initiated the phase 3 POD1UM-303/InterAACT 2 trial (NCT04472429) evaluating retifanlimab-dlwr (Zynyz) in patients with squamous cell anal …